Gemtesa’s manufacturer (Urovant Sciences) provides the Gemtesa Simple Savings Program. This is a financial assistance plan aimed at making Gemtesa (vibegron) — a treatment for overactive bladder in ...

NEW BRUNSWICK, N.J. — Drug maker Johnson & Johnson said Wednesday that patients applying for its HIV drug assistance program would have a more streamlined application process. The J&J Patient ...

In the search to lower out-of-pocket costs for prescription drugs, consumers will encounter a number of different coupons, discounts and assistance programs available to them. They don't all work the ...

Patient assistance programs and the 340B Drug Pricing Program promise to improve the financial stability, better serve vulnerable patients, and decrease the burden of cost for uninsured patients. Our ...

Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study One potential solution to ease the ...

Implementing patient cost sharing in the form of copayments, coinsurance, and deductibles is one of the more reliable methods for reducing health care costs. But imposing cost sharing reduces patients ...

The Patient Advocate Foundation and Patient Access Network together awarded more than $640 million of financial support to nearly 200,000 people in 2025. Combining will help them ramp up that support ...

Limited evidence from a literature review suggests that co-pay assistance was associated with improved treatment persistence/adherence across various diseases, with indirect evidence suggesting ...

Gilead therefore supports and will participate in a new collaboration between industry and community partners to develop a universal application system for patient assistance programs that would ...

Do Patients and Oncologists Discuss the Cost of Cancer Treatment? An Observational Study of Clinical Interactions Between African American Patients and Their Oncologists Pharmaceutical manufacturers ...

In honor of Rare Disease Day on February 28, 2025, we will publish a series of posts throughout the month on As Prescribed and Health Law Scan, focusing on issues impacting the rare disease community.